Relapsed/Refractory Patients:

Treatment Options - Marizomib (NPI-0052)


Marizomib (NPI-0052)


What is Marizomib?

Marizomib (NPI-0052) is a proteasome inhibitor being developed by Nereus Pharmaceuticals that is being evaluated in myeloma and other cancers. Marizomib is in the same class of agents as Velcade® (bortezomib), but it has a different structure. Proteasomes are enzymes found in cells and play an important role in regulating cell function and growth by controlling the breakdown of important proteins. Marizomib blocks the activity of proteasomes and by blocking the proteasome, it disrupts processes related to the growth and survival of cancer cells. Marizomib is given as an intravenous infusion.

What do we know about Marizomib’s activity in myeloma?

Marizomib has been shown to have potent anti-myeloma activity in the laboratory and in animal models of myeloma. Marizomib is active against multiple myeloma cells that are resistant to Velcade, Revlimid® (lenalidomide), Thalomid® (thalidomide), and corticosteroids.

How is Marizomib currently being studied in myeloma?

Marizomib, alone and in combination with dexamethasone, is currently being evaluated in patients with relapsed or relapsed/refractory myeloma in an ongoing phase I trial that is being facilitated by the Multiple Myeloma Research Consortium (MMRC). Preliminary results from this study and a study in Australia suggest that NPI-0052 is generally well tolerated and displays clinical activity, with responses seen in patients whose disease stopped responding to Velcade. Peripheral neuropathy, a side effect sometimes seen with the proteasome inhibitor Velcade, was infrequent.

To find a clinical trial, call 1-866-603-MMCT (-6628) or click here to go to the MMRF Patient Navigator Program.